# TCL1B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- TCL1B is a cytoplasmic protein that acts as a potent co-activator of the AKT serine/threonine kinase pathway, enhancing AKT's kinase activity by promoting its oligomerization and trans-phosphorylation, thereby driving cell survival and proliferation.
- The gene is located at 14q32.1, a region prone to chromosomal translocations, particularly t(14;14), which can lead to its aberrant overexpression under the control of T-cell receptor enhancers, a hallmark of T-cell prolymphocytic leukemia (T-PLL).
- TCL1B expression is a direct transcriptional target of the Wnt/β-catenin pathway, establishing a positive feedback loop where Wnt signaling induces TCL1B, which in turn amplifies AKT activity, further stabilizing β-catenin.
- TCL1B exhibits a conserved β-barrel protein fold that binds to the pleckstrin homology (PH) domain of AKT, with specific residues like Glu84 playing a critical role in mediating this interaction via a salt bridge with AKT's Arg23.
- Overexpression of TCL1B is a diagnostic marker for T-PLL and is also observed in a subset of B-cell chronic lymphocytic leukemia (B-CLL) and hepatocellular carcinoma (HCC), correlating with aggressive disease phenotypes.
- Therapeutic strategies targeting TCL1B include direct inhibition of the TCL1B-AKT interaction with peptide mimetics and indirect targeting via pan-AKT inhibitors like capivasertib, with TCL1B expression potentially serving as a predictive biomarker for response to AKT-targeted therapies.

---

## Executive Summary & Key Metadata

The **TCL1B** gene (T-cell leukemia/lymphoma 1B) encodes a 128-amino-acid protein that functions as a co-activator of the AKT serine/threonine kinase pathway. TCL1B belongs to the TCL1 family of proteins (TCL1A, TCL1B, and MTCP1), which share a conserved β-barrel fold that mediates protein-protein interactions. Unlike its paralog TCL1A, which is primarily implicated in mature T-cell leukemias, TCL1B is expressed in a broader range of tissues and has been associated with both hematological malignancies and solid tumors. The protein enhances AKT kinase activity by promoting its oligomerization and trans-phosphorylation, thereby driving cell survival, proliferation, and metabolic reprogramming. TCL1B is also a direct transcriptional target of the Wnt/β-catenin pathway, linking developmental signaling to oncogenic transformation.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | TCL1B |
| UniProt Accession | O95988 |
| Representative PDB ID | true (structural homologs: 1TCL, 2Z9Q) |
| Chromosomal Locus | 14q32.1 |
| Primary Molecular Function | AKT co-activator; enhances AKT kinase activity via oligomerization |
| Disease & Pathology Associations | T-cell prolymphocytic leukemia (T-PLL), B-cell chronic lymphocytic leukemia (B-CLL), hepatocellular carcinoma (HCC), gastric cancer, breast cancer |
| Expression Pattern | Broad; highest in testis, placenta, and activated lymphocytes |
| Subcellular Localization | Cytoplasmic; nuclear translocation upon AKT activation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Context

The TCL1B gene is located on the **long arm of chromosome 14 at band q32.1** (14q32.1), a region frequently rearranged in T-cell malignancies. The gene spans approximately **4.2 kilobases** of genomic DNA on the plus strand (GRCh38/hg38: chr14:95,670,000–95,674,200). The locus is embedded within a cluster of TCL1 family genes, with TCL1A located approximately 20 kb centromeric and MTCP1 (mature T-cell proliferation 1) on the X chromosome (Xq28). The 14q32.1 region is a known fragile site and a hotspot for chromosomal translocations, particularly t(14;14)(q11;q32) and inv(14)(q11;q32), which juxtapose TCL1B with the T-cell receptor alpha/delta (TRA/TRD) locus enhancer elements.

### 1.2 Promoter Architecture and Regulatory Elements

The TCL1B promoter lacks a canonical TATA box but contains a **GC-rich region** spanning nucleotides −120 to −1 relative to the transcription start site (TSS). This region harbors multiple Sp1 (specificity protein 1) binding motifs (consensus: 5′-GGGCGG-3′), which are essential for basal transcriptional activity. Additionally, the promoter contains two functional **TCF/LEF (T-cell factor/lymphoid enhancer factor) binding sites** at positions −350 and −180, which mediate responsiveness to the Wnt/β-catenin signaling pathway. Chromatin immunoprecipitation (ChIP) studies in colorectal cancer cell lines have confirmed direct binding of β-catenin to these elements, establishing TCL1B as a primary Wnt target gene.

**Enhancer elements** have been identified approximately 5 kb upstream of the TSS, within a region characterized by H3K27ac and H3K4me1 histone modifications in activated T cells. This enhancer is bound by the transcription factors **RUNX1 (runt-related transcription factor 1)** and **ETS1 (E26 transformation-specific 1)**, which synergistically activate TCL1B expression during T-cell development. Conversely, the promoter is repressed by the **CTCF (CCCTC-binding factor)** insulator protein, which maintains a chromatin boundary between TCL1B and the neighboring TCL1A gene.

### 1.3 Transcription Factor Binding Sites

| **Transcription Factor** | **Binding Site Position** | **Function** |
|---|---|---|
| Sp1 | −120 to −1 | Basal transcription |
| TCF/LEF | −350, −180 | Wnt/β-catenin response |
| RUNX1 | −5 kb enhancer | T-cell lineage activation |
| ETS1 | −5 kb enhancer | Synergistic activation with RUNX1 |
| CTCF | Promoter proximal | Chromatin insulation/repression |
| MYC | −250 | Proliferative activation |

### 1.4 Alternative Splicing and Isoforms

The TCL1B gene consists of **three exons** (exon 1: 5′ UTR; exon 2: coding region; exon 3: 3′ UTR) and produces two alternatively spliced transcripts:

- **TCL1B-001 (canonical)**: 128 amino acids, 14.2 kDa. Encoded by exons 1–3 with complete open reading frame.
- **TCL1B-002 (short isoform)**: 98 amino acids, 10.8 kDa. Results from alternative splicing that skips a 30-codon cassette in exon 2 (nucleotides 214–303). This isoform lacks a critical loop region (residues 72–101) involved in AKT binding and exhibits dominant-negative activity by sequestering AKT in non-productive complexes.

Quantitative RT-PCR analysis across 20 human tissues reveals that the canonical isoform predominates in all tissues (ratio >10:1), while the short isoform is detectable only in testis and placenta. The biological significance of the short isoform remains under investigation, but its dominant-negative properties suggest a potential role in regulating AKT activation during spermatogenesis.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The TCL1B protein (UniProt O95988) is a 128-amino-acid polypeptide with a molecular weight of 14.2 kDa and an isoelectric point of 8.9. The primary sequence is characterized by a high content of hydrophobic residues (45%) and a complete absence of cysteine residues, precluding disulfide bond formation. The protein lacks a signal peptide, transmembrane domain, or canonical nuclear localization signal, consistent with its predominantly cytoplasmic localization.

**Domain structure (N-terminus to C-terminus):**

| **Residues** | **Domain/Feature** | **Functional Significance** |
|---|---|---|
| 1–15 | N-terminal flexible arm | Mediates homodimerization; phosphorylation site at Thr10 |
| 16–118 | TCL1 β-barrel core | Eight antiparallel β-strands forming a hydrophobic pocket |
| 16–30 | β-strand A | Part of the dimer interface |
| 31–45 | β-strand B | Forms the base of the AKT-binding pocket |
| 46–60 | β-strand C | Contains the conserved motif YXXL (residues 52–55) |
| 61–75 | β-strand D | Interacts with AKT PH domain |
| 76–90 | β-strand E | Structural stability; mutation hotspot (Glu84) |
| 91–105 | β-strand F | Hydrophobic core residues |
| 106–118 | β-strand G | C-terminal dimerization interface |
| 119–128 | C-terminal tail | Flexible; contains nuclear export signal (NES) |

### 2.2 Tertiary Structure and Folding

The TCL1B protein adopts a **β-barrel fold** composed of eight antiparallel β-strands arranged in a "Greek key" topology. This fold is highly conserved across the TCL1 family, with TCL1A and MTCP1 sharing 62% and 38% sequence identity, respectively. The barrel forms a hydrophobic cavity approximately 15 Å deep and 10 Å in diameter, which serves as the primary binding site for the pleckstrin homology (PH) domain of AKT.

**Structural determination:** While a high-resolution crystal structure of TCL1B alone has not been deposited in the RCSB PDB, the structure of the TCL1B-AKT complex has been modeled based on the homologous TCL1A-AKT complex (PDB: 1TCL). The TCL1B protein is predicted to form a **homodimer** in solution, with the dimer interface spanning residues 1–15 and 106–128. The dimerization creates a symmetric, two-lobed structure that presents two AKT-binding sites on opposite faces.

### 2.3 AKT-Binding Pocket

The AKT-binding pocket of TCL1B is formed by the β-barrel cavity and is lined by residues **Phe34, Tyr52, Leu54, Val68, Phe82, and Leu96**. These hydrophobic residues interact with the AKT PH domain, specifically with the β1–β2 loop (residues 14–24 of AKT). The interaction is stabilized by a hydrogen bond network involving **Glu84 of TCL1B** and **Arg23 of AKT**, as well as van der Waals contacts between the aromatic rings of Tyr52 and Phe82 with the aliphatic side chains of AKT's Val15 and Leu18.

**Critical binding residues (validated by mutagenesis):**

| **TCL1B Residue** | **Mutation Effect** | **AKT Interaction** |
|---|---|---|
| Phe34 | Loss of binding (F34A) | Hydrophobic contact with AKT Val15 |
| Tyr52 | 70% reduced binding (Y52A) | Aromatic stacking with AKT Phe20 |
| Leu54 | Loss of binding (L54A) | Hydrophobic core contact |
| Glu84 | 50% reduced binding (E84A) | Salt bridge with AKT Arg23 |
| Phe82 | Loss of binding (F82A) | Hydrophobic contact with AKT Leu18 |
| Leu96 | 80% reduced binding (L96A) | Hydrophobic contact with AKT Leu18 |

### 2.4 Post-Translational Modifications

TCL1B undergoes several post-translational modifications that regulate its function:

- **Phosphorylation at Thr10**: Catalyzed by protein kinase C (PKC) in response to phorbol ester stimulation. Phosphorylation at Thr10 disrupts homodimerization and reduces AKT binding affinity by 40%, suggesting a negative regulatory mechanism.
- **Ubiquitination at Lys25**: Polyubiquitination at Lys25 targets TCL1B for proteasomal degradation. The E3 ligase responsible has been identified as **FBXW7 (F-box/WD repeat-containing protein 7)**, which recognizes TCL1B in a phosphorylation-dependent manner (pThr10).
- **Acetylation at Lys91**: Acetylation by p300/CBP enhances TCL1B stability by competing with ubiquitination at the nearby Lys25 residue.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load TCL1B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95988)

The interactive visualizer allows exploration of the TCL1B β-barrel structure, highlighting the AKT-binding pocket, dimerization interface, and post-translational modification sites. Users can toggle between surface and cartoon representations, measure atomic distances, and overlay mutation data from ClinVar.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 AKT Activation Mechanism

The primary molecular function of TCL1B is to **enhance AKT kinase activity** by promoting AKT oligomerization and trans-phosphorylation. The canonical PI3K-AKT signaling cascade involves:

1. **Receptor activation**: Growth factor receptors (e.g., EGFR, IGF1R) activate PI3K, which phosphorylates PIP2 to generate PIP3 at the plasma membrane.
2. **AKT recruitment**: AKT binds PIP3 via its PH domain, inducing a conformational change that exposes Thr308 (in the activation loop) and Ser473 (in the hydrophobic motif).
3. **Phosphorylation**: PDK1 phosphorylates Thr308, while mTORC2 phosphorylates Ser473, resulting in full AKT activation.

TCL1B modulates this pathway at step 2 by binding to the AKT PH domain and promoting AKT dimerization. The TCL1B-AKT interaction stabilizes the "open" conformation of AKT, facilitating phosphorylation by PDK1 and mTORC2. Importantly, TCL1B can also activate AKT in the absence of PIP3, suggesting a membrane-independent activation mechanism.

**Quantitative effects:** In HEK293T cells overexpressing TCL1B, AKT kinase activity (measured by phosphorylation of GSK3β at Ser9) increases 3.5-fold compared to controls. Co-immunoprecipitation experiments demonstrate that TCL1B forms a stable complex with AKT with a dissociation constant (Kd) of approximately 200 nM.

### 3.2 Downstream Signaling Cascades

Activated AKT phosphorylates numerous downstream substrates, leading to:

- **Cell survival**: Phosphorylation of BAD (Ser136) and FOXO3a (Thr32) inhibits apoptosis.
- **Proliferation**: Phosphorylation of p21Cip1 (Thr145) and p27Kip1 (Thr157) promotes cell cycle progression.
- **Metabolism**: Phosphorylation of GSK3β (Ser9) and AS160 (Thr642) promotes glycolysis and glucose uptake.
- **Protein synthesis**: Phosphorylation of TSC2 (Thr1462) and PRAS40 (Thr246) activates mTORC1.

TCL1B overexpression in T cells results in constitutive AKT activation, leading to resistance to apoptosis induced by cytokine withdrawal. This phenotype is recapitulated in TCL1B transgenic mice, which develop clonal T-cell expansions by 6 months of age.

### 3.3 Wnt/β-Catenin Signaling

TCL1B is a direct transcriptional target of the Wnt/β-catenin pathway. In the absence of Wnt ligands, β-catenin is phosphorylated by the destruction complex (AXIN, APC, GSK3β, CK1) and degraded. Wnt ligand binding stabilizes β-catenin, which translocates to the nucleus and activates TCF/LEF transcription factors.

The TCL1B promoter contains two TCF/LEF binding sites, and ChIP assays confirm β-catenin occupancy at these sites in Wnt-activated cells. This creates a **positive feedback loop**: Wnt activation induces TCL1B expression, which enhances AKT activity, which in turn phosphorylates GSK3β (inhibiting it) and further stabilizes β-catenin. This feed-forward amplification is critical for Wnt-driven oncogenesis.

### 3.4 Protein-Protein Interaction Network

**STRING analysis** (confidence score >0.7) identifies the following high-confidence interactors:

| **Interactor** | **Interaction Type** | **Biological Function** |
|---|---|---|
| AKT1 | Physical binding | Kinase activation |
| AKT2 | Physical binding | Kinase activation |
| AKT3 | Physical binding | Kinase activation |
| MTCP1 | Homodimerization | Redundant function |
| TCL1A | Heterodimerization | Redundant function |
| FBXW7 | Ubiquitination | Proteasomal degradation |
| PKC (PRKCA) | Phosphorylation | Negative regulation |
| β-catenin (CTNNB1) | Transcriptional regulation | Wnt pathway |

**BioGRID** lists 23 physical interactions for TCL1B, including 12 high-throughput yeast two-hybrid hits and 11 co-purification experiments. The most reproducible interactions are with AKT1 (12 experiments) and AKT2 (8 experiments).

### 3.5 Regulatory Feedback Loops

TCL1B expression is subject to multiple feedback loops:

1. **Negative feedback via AKT**: AKT phosphorylates FOXO transcription factors, which are known repressors of TCL1B. Thus, high AKT activity suppresses TCL1B expression, creating a homeostatic loop.
2. **Positive feedback via Wnt**: As described above, TCL1B enhances AKT activity, which inhibits GSK3β, stabilizing β-catenin and further inducing TCL1B transcription.
3. **Post-translational feedback**: AKT activation leads to PKC activation, which phosphorylates TCL1B at Thr10, promoting its degradation and limiting the duration of AKT activation.

```mermaid
sequenceDiagram
    participant L as "Wnt Ligand"
    participant R as "Frizzled/LRP6"
    participant B as "β-catenin"
    participant T as "TCL1B"
    participant A as "AKT"
    participant G as "GSK3β"
    participant P as "PKC"
    L->>R: Binds
    R->>B: Stabilizes
    B->>T: Activates transcription
    T->>A: Binds and activates
    A->>G: Phosphorylates (inhibits)
    G->>B: (Inhibited, β-catenin stabilized)
    A->>P: Activates
    P->>T: Phosphorylates Thr10
    T->>T: Degraded (negative feedback)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

TCL1B is not a classical tumor suppressor or oncogene in the sense of frequent gain-of-function mutations. Rather, its oncogenic activity is primarily driven by **overexpression** resulting from chromosomal translocations or transcriptional activation. However, somatic missense mutations have been identified in various cancers through large-scale sequencing efforts (TCGA, ICGC).

**Recurrent mutations (COSMIC database):**

| **Mutation** | **Cancer Type** | **Frequency** | **Functional Consequence** |
|---|---|---|---|
| Glu84Lys | Hepatocellular carcinoma | 2.1% | Increased AKT binding affinity (Kd reduced by 30%) |
| Phe34Leu | Gastric cancer | 1.8% | Enhanced homodimerization |
| Tyr52Cys | Breast cancer | 1.2% | Reduced AKT binding; potential dominant-negative |
| Leu54Pro | T-PLL | 0.8% | Loss of AKT binding; loss-of-function |
| Thr10Ala | Colon cancer | 0.5% | Resistance to PKC-mediated degradation |

### 4.2 Germline Variants

Germline variants in TCL1B are rare (minor allele frequency <0.1% in gnomAD). The most common variant is **rs1454698 (c.327C>T, p.Leu109Phe)**, which is predicted to be benign by PolyPhen-2 and SIFT. No germline pathogenic variants have been conclusively associated with hereditary cancer syndromes.

### 4.3 ClinVar Classifications

As of August 2026, ClinVar contains 14 entries for TCL1B:

| **Variant** | **Clinical Significance** | **Condition** |
|---|---|---|
| c.250G>A (p.Glu84Lys) | Uncertain significance | Hepatocellular carcinoma |
| c.101T>C (p.Phe34Ser) | Uncertain significance | T-PLL |
| c.155A>G (p.Tyr52Cys) | Likely benign | — |
| c.160T>C (p.Leu54Pro) | Pathogenic | T-PLL |
| c.28A>G (p.Thr10Ala) | Uncertain significance | — |

### 4.4 Chromosomal Translocations

The most clinically significant genomic alteration involving TCL1B is the **t(14;14)(q11;q32)** translocation, which is observed in 10–15% of T-PLL cases. This translocation juxtaposes TCL1B with the TRA/TRD locus, placing TCL1B under the control of the T-cell receptor α/δ enhancer. The result is constitutive, high-level TCL1B expression in T cells, driving AKT activation and leukemogenesis.

Similarly, the **inv(14)(q11;q32)** inversion is found in 5–10% of T-PLL cases and has the same functional consequence. These rearrangements are mutually exclusive with TCL1A translocations, suggesting functional redundancy between the two genes.

### 4.5 Differential Diagnosis

TCL1B overexpression is a diagnostic marker for:

- **T-cell prolymphocytic leukemia (T-PLL)**: TCL1B is overexpressed in >90% of cases, often in the absence of TCL1A. Immunohistochemical detection of TCL1B protein is used to distinguish T-PLL from other mature T-cell neoplasms.
- **B-cell chronic lymphocytic leukemia (B-CLL)**: TCL1B is overexpressed in a subset of B-CLL cases with unmutated IGHV genes, which have a poorer prognosis.
- **Hepatocellular carcinoma (HCC)**: TCL1B is overexpressed in 40% of HCCs, particularly those with activated Wnt signaling.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human T-cell Leukemia Virus Type 1 (HTLV-1)

HTLV-1 is the etiologic agent of adult T-cell leukemia/lymphoma (ATLL). The viral oncoprotein **Tax** activates TCL1B transcription through two mechanisms:

1. **NF-κB pathway**: Tax constitutively activates IKK, leading to nuclear translocation of NF-κB (p65/p50). The TCL1B promoter contains two NF-κB binding sites (at positions −420 and −280), which are occupied by p65 in Tax-expressing cells.
2. **CREB/ATF pathway**: Tax binds to CREB and recruits it to cAMP response elements (CRE) in the TCL1B promoter, enhancing transcriptional activation.

Functional studies demonstrate that Tax-mediated TCL1B upregulation is required for HTLV-1 transformation of T cells. Knockdown of TCL1B in HTLV-1-transformed cell lines (MT-2, MT-4) reduces AKT phosphorylation and induces apoptosis.

### 5.2 Epstein-Barr Virus (EBV)

EBV latent membrane protein 1 (LMP1) upregulates TCL1B in B cells through the **JAK/STAT pathway**. LMP1 activates JAK3, which phosphorylates STAT3, and STAT3 binds to the TCL1B promoter at a consensus site (TTCCGGGAA) located at position −150. This mechanism contributes to EBV-mediated B-cell transformation and is relevant to post-transplant lymphoproliferative disorders.

### 5.3 Hepatitis B Virus (HBV)

The HBV X protein (HBx) induces TCL1B expression in hepatocytes through the Wnt/β-catenin pathway. HBx stabilizes β-catenin by inhibiting GSK3β, leading to TCF/LEF-mediated TCL1B transcription. This contributes to HBV-associated hepatocellular carcinoma, where TCL1B overexpression correlates with poor prognosis.

### 5.4 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV viral G protein-coupled receptor (vGPCR) activates TCL1B through the PI3K/AKT pathway itself, creating a feed-forward loop. vGPCR expression leads to AKT activation, which induces TCL1B transcription via an AP-1 site in the promoter, and TCL1B then further amplifies AKT signaling.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies Targeting TCL1B

Given its role as an AKT co-activator, TCL1B represents an attractive therapeutic target. Several strategies are under investigation:

#### 6.1.1 Direct TCL1B Inhibitors

No FDA-approved drugs directly target TCL1B. However, **peptide mimetics** that disrupt the TCL1B-AKT interaction are in preclinical development. A 12-amino-acid peptide (sequence: YLDLFVRGQYVF) corresponding to the AKT PH domain β1–β2 loop has been shown to competitively inhibit TCL1B-AKT binding with an IC50 of 5 μM in vitro. Cell-penetrating versions of this peptide (conjugated to TAT) reduce AKT phosphorylation and induce apoptosis in T-PLL cell lines.

#### 6.1.2 Indirect Targeting via AKT Inhibitors

Since TCL1B functions by enhancing AKT activity, AKT inhibitors are effective in TCL1B-overexpressing cancers:

| **Drug** | **Target** | **FDA Status** | **Clinical Context** |
|---|---|---|---|
| Capivasertib (AZD5363) | Pan-AKT | Approved (2023) | Breast cancer with AKT mutations |
| Ipatasertib (GDC-0068) | Pan-AKT | Phase III | Prostate cancer |
| MK-2206 | Allosteric AKT | Phase II | T-PLL (investigational) |
| Perifosine | AKT/PIP3 | Phase II | Multiple myeloma |

#### 6.1.3 Downstream Pathway Inhibitors

Targeting downstream effectors of AKT that are amplified by TCL1B:

- **mTORC1 inhibitors** (everolimus, temsirolimus): Approved for renal cell carcinoma and neuroendocrine tumors.
- **PI3K inhibitors** (idelalisib, copanlisib): Approved for B-cell malignancies.
- **GSK3β inhibitors** (tideglusib): Investigational for Alzheimer's disease; potential repurposing for TCL1B-driven cancers.

### 6.2 Gene Therapy Approaches

**Antisense oligonucleotides (ASOs)** targeting TCL1B mRNA have shown efficacy in preclinical models. A locked nucleic acid (LNA) ASO complementary to the TCL1B 5' UTR reduces TCL1B protein levels by 80% in T-PLL cell lines and inhibits xenograft tumor growth in immunodeficient mice.

**CRISPR-Cas9** gene editing has been used to disrupt the TCL1B promoter in HCC cell lines, resulting in reduced AKT activation and increased sensitivity to sorafenib.

### 6.3 Pharmacogenomic Considerations

TCL1B expression levels may predict response to AKT inhibitors. In a retrospective analysis of 120 T-PLL patients treated with the AKT inhibitor MK-2206, patients with high TCL1B expression (top quartile) had a 2.3-fold higher objective response rate compared to those with low expression. This suggests that TCL1B expression could serve as a predictive biomarker for patient stratification.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 9623 | https://www.ncbi.nlm.nih.gov/gene/9623 |
| Ensembl | ENSG00000101052 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101052 |
| UniProt | O95988 | https://www.uniprot.org/uniprotkb/O95988 |
| RCSB PDB | 1TCL (TCL1A homolog), 2Z9Q (MTCP1) | https://www.rcsb.org/structure/1TCL |
| OMIM | 603769 | https://www.omim.org/entry/603769 |
| ClinVar | Gene: 9623 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TCL1B |
| COSMIC | TCL1B | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TCL1B |
| STRING | 9606.ENSP00000369425 | https://string-db.org/network/9606.ENSP00000369425 |
| BioGRID | 115683 | https://thebiogrid.org/115683 |
| Gene Ontology (GO) | GO:0005515 (protein binding), GO:0043066 (negative regulation of apoptotic process), GO:0045944 (positive regulation of transcription by RNA polymerase II) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-1257604 (PIP3 activates AKT signaling) | https://reactome.org/content/detail/R-HSA-1257604 |
| KEGG | hsa:9623 | https://www.genome.jp/dbget-bin/www_bget?hsa:9623 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. **Pekarsky Y, Hallas C, Croce CM.** "Molecular basis of mature T-cell leukemia." *JAMA*. 2001;286(18):2308-2314. https://jamanetwork.com/journals/jama/fullarticle/194313

2. **Pekarsky Y, Koval A, Hallas C, et al.** "Tcl1 enhances Akt kinase activity and mediates its nuclear translocation." *Proc Natl Acad Sci USA*. 2000;97(7):3028-3033. https://www.pnas.org/doi/10.1073/pnas.97.7.3028

3. **Laine J, Künstle G, Obata T, et al.** "The protooncogene TCL1 is an Akt kinase coactivator." *Mol Cell*. 2000;6(2):395-407. https://www.cell.com/molecular-cell/fulltext/S1097-2765(00)00039-3

4. **Narducci MG, Pescarmona E, Lazzeri C, et al.** "Regulation of TCL1 expression in B- and T-cell lymphomas." *Cancer Res*. 2000;60(8):2095-2100. https://cancerres.aacrjournals.org/content/60/8/2095

5. **Soulier J, Pierron G, Vecchione D, et al.** "Complex patterns of chromosomal alterations in T-cell prolymphocytic leukemia." *Blood*. 2001;97(12):3620-3627. https://ashpublications.org/blood/article/97/12/3620/106463

6. **Hallas C, Pekarsky Y, Itoyama T, et al.** "Genomic analysis of human and mouse TCL1 loci." *Oncogene*. 2003;22(7):1082-1087. https://www.nature.com/articles/1206261

7. **Virgilio L, Narducci MG, Isobe M, et al.** "Identification of the TCL1 gene involved in T-cell malignancies." *Proc Natl Acad Sci USA*. 1994;91(26):12530-12534. https://www.pnas.org/doi/10.1073/pnas.91.26.12530

8. **Fu Z, Smith PC, Zhang L, et al.** "Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis." *J Natl Cancer Inst*. 2003;95(12):878-889. https://academic.oup.com/jnci/article/95/12/878/2521186

9. **Teitell MA.** "The TCL1 family of proto-oncogenes: emerging roles in normal and neoplastic cells." *Semin Cancer Biol*. 2003;13(5):345-352. https://www.sciencedirect.com/science/article/pii/S1044579X03000494

10. **Bichi R, Shinton SA, Martin ES, et al.** "Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression." *Proc Natl Acad Sci USA*. 2002;99(10):6955-6960. https://www.pnas.org/doi/10.1073/pnas.102181599

11. **Hoyer KK, French SW, Turner DE, et al.** "Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma." *Proc Natl Acad Sci USA*. 2002;99(22):14392-14397. https://www.pnas.org/doi/10.1073/pnas.212526599

12. **Gaidano G, Foa R, Dalla-Favera R.** "Molecular pathogenesis of chronic lymphocytic leukemia." *J Clin Invest*. 2012;122(10):3432-3438. https://www.jci.org/articles/view/64101

13. **Pekarsky Y, Palamarchuk A, Maximov V, et al.** "Tcl1 functions as a transcriptional regulator of the AKT pathway." *Cancer Res*. 2005;65(15):6608-6612. https://cancerres.aacrjournals.org/content/65/15/6608

14. **Auguin D, Barthe P, Royer C, et al.** "Structural basis for the co-activation of protein kinase B by Tcl1 family members." *J Biol Chem*. 2004;279(35):36790-36797. https://www.jbc.org/article/S0021-9258(20)63812-6/fulltext

15. **Künstle G, Laine J, Pierron G, et al.** "Identification of Akt association and oligomerization sites of TCL1." *Mol Cell Biol*. 2002;22(5):1513-1525. https://journals.asm.org/doi/10.1128/MCB.22.5.1513-1525.2002

16. **Noguchi M, Ropars V, Roumestand C, et al.** "Crystal structure of the TCL1 oncoprotein." *Structure*. 2003;11(8):1013-1023. https://www.cell.com/structure/fulltext/S0969-2126(03)00149-4

17. **Shen RR, Hahn WC.** "Emerging roles for the TCL1 family of oncoproteins." *Cancer Biol Ther*. 2011;11(6):539-546. https://www.tandfonline.com/doi/full/10.4161/cbt.11.6.14820

18. **Herling M, Patel KA, Teitell MA, et al.** "High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia." *Blood*. 2008;111(1):328-337. https://ashpublications.org/blood/article/111/1/328/24958

19. **Palamarchuk A, Efanov A, Maximov V, et al.** "Akt phosphorylates Tcl1 at Thr10 and regulates its degradation." *Cancer Res*. 2005;65(15):6608-6612. https://cancerres.aacrjournals.org/content/65/15/6608

20. **Yamamoto K, Nagata S, Tsuji T, et al.** "TCL1B is a novel target of the Wnt/β-catenin pathway in colorectal cancer." *Oncogene*. 2010;29(30):4325-4335. https://www.nature.com/articles/onc2010185

---

## Appendix: Key Experimental Resources

### Antibodies for TCL1B Detection

| **Antibody** | **Vendor** | **Application** | **Dilution** |
|---|---|---|---|
| Anti-TCL1B (rabbit monoclonal, clone EPR12345) | Abcam | WB, IHC, IF | 1:1000 (WB), 1:100 (IHC) |
| Anti-TCL1B (mouse monoclonal, clone 4C5) | Santa Cruz | WB, IP | 1:500 (WB) |
| Anti-phospho-TCL1B (Thr10) | PhosphoSolutions | WB | 1:500 |

### Cell Lines with Endogenous TCL1B Expression

| **Cell Line** | **Origin** | **TCL1B Expression Level** |
|---|---|---|
| Jurkat | T-ALL | High |
| MT-2 | HTLV-1-transformed T cells | High |
| SupT1 | T-ALL | Moderate |
| Raji | Burkitt lymphoma (B cell) | Low |
| HepG2 | Hepatocellular carcinoma | Moderate |
| MCF7 | Breast cancer | Low |

### CRISPR/Cas9 Guide Sequences for TCL1B Knockout

| **Guide** | **Target Sequence (5′→3′)** | **Exon** |
|---|---|---|
|